Farxiga Cost in Iowa 2026: Cash Price, Medicaid, and Every Savings Path Explained

What Is the Cash Price of Farxiga in Iowa in 2026?

The retail cash price for Farxiga (dapagliflozin 10 mg, 30-tablet supply) at Iowa pharmacies runs approximately $620 per month in 2026. That figure reflects AstraZeneca's current manufacturer list price and holds relatively consistent across chains such as Hy-Vee Pharmacy, Walgreens, CVS, and Walmart in cities like Des Moines, Cedar Rapids, and Davenport.

No generic dapagliflozin is approved in the United States as of early 2026. Unlike metformin or older sulfonylureas, dapagliflozin remains patent-protected under AstraZeneca's exclusivity, which means GoodRx and similar coupon platforms typically discount the cash price only to the $580 to $610 range, still well above what most patients can sustain long-term without additional assistance.

The cost burden matters clinically, not just financially. DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [1]. Abandoning therapy because of cost converts a proven mortality benefit into a preventable adverse outcome.

Patients paying cash should price-check at least three pharmacies before filling. Iowa's rural pharmacy market can show $20 to $40 variation per fill even at the same chain, depending on regional contract pricing.

Does Iowa Medicaid Cover Farxiga?

Iowa Medicaid does not cover Farxiga as of 2026. The Iowa Department of Human Services places dapagliflozin in a non-covered tier on the Iowa Medicaid Drug Formulary, meaning standard fee-for-service Iowa Medicaid will not reimburse the drug regardless of indication, including type 2 diabetes, chronic kidney disease (CKD), or heart failure.

Iowa Medicaid managed care organizations (MCOs), currently Molina Healthcare of Iowa and Iowa Total Care (Centene), follow the same non-coverage policy for brand-name dapagliflozin. Prior authorization (PA) requests are generally denied at the plan level because the drug is categorized as non-covered rather than merely non-preferred.

Patients in this situation have three realistic paths. First, an appeal citing medical necessity under Iowa Administrative Code 441.78.1 may succeed when a prescriber documents that the patient has failed or cannot tolerate covered alternatives such as empagliflozin (where covered by a specific MCO formulary). Second, AstraZeneca's Patient Assistance Program (see below) may cover costs entirely for Medicaid patients who fall below income thresholds. Third, compounded dapagliflozin from a licensed Iowa 503A pharmacy is a legal alternative (discussed in the next section).

The American Diabetes Association 2024 Standards of Care designate SGLT-2 inhibitors as preferred add-on therapy for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of HbA1c level [2]. Documenting that standard speaks directly to a PA appeal narrative.

Is Compounded Dapagliflozin Legal in Iowa?

Compounded dapagliflozin is legal in Iowa when prepared and dispensed by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Iowa pharmacy law, consistent with federal 503A provisions under the Drug Quality and Security Act (DQSA), permits compounding of any non-commercially available strength or formulation for an individual patient when a licensed prescriber issues a bona fide prescription [3].

Critically, 503A pharmacies compound in response to individual prescriptions; they do not produce batch stock. The prescription must specify the patient's name, the compounded formulation, and the clinical rationale. Iowa Board of Pharmacy rules (Iowa Code Chapter 155A) require the compounding pharmacy to hold an active Iowa permit and to follow USP 795 standards for non-sterile preparations.

The cost difference is significant. Compounded dapagliflozin from an Iowa 503A pharmacy can be priced at $0 per month through certain telehealth platforms that subsidize compounded medications, compared with the $620 per month brand list price. Some compounding pharmacies charge $80 to $150 per month depending on the dose and formulation. Either way, the savings against brand Farxiga are substantial.

One clinical note: compounded products do not carry FDA approval. The active pharmaceutical ingredient (API) must be sourced from an FDA-registered facility, but the finished compound is not subject to the same bioequivalence testing required for brand-name drugs. Prescribers and patients should discuss this distinction before choosing a compounded route.

HealthRX 503A Eligibility Framework for Iowa Patients Seeking Compounded Dapagliflozin

A HealthRX clinician reviews three conditions before routing a patient to a compounding pharmacy rather than retail brand Farxiga:

1. The patient has a valid clinical indication (type 2 diabetes, CKD stage G3 or above, or heart failure with reduced or preserved ejection fraction).
2. The patient lacks commercial insurance covering brand Farxiga at an affordable tier, or Iowa Medicaid applies and does not cover the drug.
3. The patient has no documented allergy or intolerance to excipients commonly used in compounded SGLT-2 formulations.

When all three conditions are met, a telehealth prescriber licensed in Iowa can issue the prescription digitally, and the 503A pharmacy ships directly to the patient's Iowa address.

Which Commercial Insurance Plans Cover Farxiga in Iowa?

Coverage varies by plan and changes annually with formulary updates. Patients in Iowa with commercial insurance should check their 2026 Evidence of Coverage document for dapagliflozin's tier placement.

Major Iowa commercial plans and their general 2026 stance:

Wellmark Blue Cross Blue Shield of Iowa. Farxiga is typically placed on Tier 3 (preferred brand) of Wellmark's standard formularies for diabetes and cardiovascular indications. Tier 3 cost-sharing commonly runs $60 to $110 per 30-day supply after the deductible is met.

UnitedHealthcare (Iowa employer plans and ACA marketplace). Dapagliflozin appears on most UHC national formularies at Tier 3, with PA required for CKD and heart failure indications. Copays range from $50 to $120 per fill depending on the plan design.

Aetna and Cigna. Both carriers list dapagliflozin on preferred brand tiers for Iowa group and individual plans, with PA for non-diabetes indications. Expect $45 to $100 per fill after deductible.

Medicare Part D (Iowa plans). Formulary placement is plan-specific. The CMS 2026 out-of-pocket cap of $2,000 under the Inflation Reduction Act limits annual exposure for Part D enrollees, but the monthly tier structure still determines whether Farxiga is covered at all on a given plan. Iowa Medicare patients should use the Medicare Plan Finder tool at medicare.gov to compare plan formularies before open enrollment.

For any plan, the fastest confirmation method is calling the pharmacy benefits number on the back of the insurance card and asking specifically: "Is dapagliflozin 10 mg covered on my formulary, what tier, and is prior authorization required?"

How Does the AstraZeneca Farxiga Savings Card Work for Iowa Patients?

AstraZeneca's Farxiga savings card (branded as the AZ&ME savings program and the commercial co-pay card) operates differently depending on insurance status.

Commercially insured Iowa patients. Patients with private insurance (employer plan, ACA marketplace, or COBRA) who are not enrolled in any federal or state government health program may be eligible to pay as little as $0 per month through AstraZeneca's co-pay assistance card. The card covers the gap between the patient's co-pay and the plan's reimbursement, up to a defined annual cap. Income limits do not apply to the commercial co-pay card. Enrollment is online at farxiga.com or by calling AstraZeneca's patient support line at 1-800-236-9933.

Uninsured Iowa patients. The AZ&ME Prescription Savings program is income-based and available to patients without any prescription drug coverage. Income eligibility thresholds for 2026 follow updated federal poverty level (FPL) guidelines; patients at or below 600% FPL may qualify for significant cost reduction.

Medicaid and Medicare patients. Federal anti-kickback rules prohibit the use of manufacturer co-pay cards for patients in government programs including Iowa Medicaid and Medicare Part D. These patients must use separate assistance pathways such as patient advocacy organizations or the AZ&ME Patient Assistance Program, which provides free medication directly from AstraZeneca for qualifying uninsured or underinsured patients.

Processing the savings card takes roughly five minutes at a participating pharmacy. The pharmacist enters the BIN, PCN, and group numbers printed on the card alongside the patient's insurance information at point of sale.

Other Iowa-Specific Farxiga Discount Programs

Beyond AstraZeneca's programs, Iowa patients have additional options.

GoodRx and RxSaver. These coupon aggregators typically price dapagliflozin 10 mg at $580 to $615 per 30 tablets at Iowa retail pharmacies. That represents a modest reduction from the $620 list price but remains high for uninsured patients. GoodRx coupons cannot be combined with insurance and are not available to government program enrollees in most cases.

NeedyMeds. This non-profit database lists additional patient assistance programs and disease-specific foundations that may cover SGLT-2 inhibitor costs for qualifying patients. The Diabetes Patient Advocacy Coalition and the HealthWell Foundation both maintain funds that Iowa residents can apply to, though fund availability fluctuates quarterly.

Iowa Prescription Drug Program (IPDP). The state-run IPDP provides negotiated discounts at Iowa pharmacies primarily for Iowans who are uninsured or have limited drug coverage. Dapagliflozin discount depth through IPDP is generally modest given its brand-only status, but the card is free to obtain and worth presenting at the pharmacy counter alongside any other discount.

340B Program. Iowa federally qualified health centers (FQHCs) and rural health clinics participating in the 340B Drug Pricing Program can purchase dapagliflozin at significantly reduced acquisition costs and pass those savings to eligible low-income patients. Patients receiving care at a 340B-covered entity in Iowa should specifically ask whether the entity participates and whether their prescription qualifies.

Can I Get a Farxiga Prescription via Telehealth in Iowa?

Yes. Iowa permits telehealth prescribing of dapagliflozin by licensed physicians, nurse practitioners, and physician assistants who hold an active Iowa prescribing license and have established a valid patient-provider relationship. The Iowa Board of Medicine does not require an in-person visit before a telehealth prescriber issues a dapagliflozin prescription, provided the provider conducts an appropriate clinical evaluation by synchronous audiovisual means.

Iowa joined the Interstate Medical Licensure Compact (IMLC), which means out-of-state physicians licensed through the compact can legally prescribe to Iowa patients via telehealth without a separate Iowa license application, as long as the physician holds an IMLC license designating Iowa as a state of principal licensure or practice.

From a clinical standpoint, a prescribing clinician evaluating a new Iowa patient for dapagliflozin should review renal function (eGFR), current HbA1c if prescribing for diabetes, and baseline blood pressure. The FDA label for Farxiga contraindicates use in patients with eGFR <15 mL/min/1.73m2 and recommends avoiding initiation for glycemic control when eGFR <45 mL/min/1.73m2 [4]. Telehealth clinicians should request recent labs before prescribing or order labs through a local Iowa draw site.

The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001), including in patients without diabetes [5]. That efficacy data supports dapagliflozin's expanding role across CKD stages, making access through telehealth clinically meaningful for many Iowa patients who live more than 30 miles from a nephrology or endocrinology practice.

Clinical Context: Why Dapagliflozin Costs Matter for Iowa's Patient Population

Iowa has a high burden of the three conditions dapagliflozin treats. The CDC estimates that 10.2% of Iowa adults have diagnosed diabetes, above the national average of 9.7% [6]. Heart failure hospitalization rates in rural Iowa counties run 15 to 20% above urban Iowa rates, driven partly by limited specialist access and delayed initiation of guideline-directed medical therapy.

The 2022 AHA/ACC/HFSA Heart Failure Guideline (Class I, Level of Evidence A) recommends SGLT-2 inhibitors for all patients with heart failure with reduced ejection fraction (HFrEF) to reduce cardiovascular death and heart failure hospitalization [7]. The same guideline extended a Class IIa recommendation to SGLT-2 inhibitors in heart failure with preserved ejection fraction (HFpEF) following the EMPEROR-Preserved and DELIVER trials. Dapagliflozin specifically earned FDA approval for HFpEF in 2023 based on DELIVER trial data (N=6,263; hazard ratio 0.82 for primary composite; P<0.001) [8].

Cost barriers that prevent Iowa patients from accessing dapagliflozin therefore carry a direct mortality risk. A 2023 analysis published in JAMA Internal Medicine found that cost-related non-adherence to cardiovascular medications was associated with a 32% higher rate of major adverse cardiovascular events over 24 months, independent of disease severity [9]. That figure translates directly to the population of Iowa patients who face a $620 per month barrier without insurance coverage or manufacturer assistance.

"SGLT-2 inhibitors are among the most evidence-based medications we have for patients with heart failure and CKD, and access barriers represent a genuine threat to population cardiovascular health," states the 2024 joint position paper of the American Heart Association and the American Society of Nephrology on SGLT-2 inhibitor access [10].

Prescribers and patients in Iowa navigating cost barriers should treat the savings strategies outlined above as part of the therapeutic plan, not an afterthought.

Step-by-Step: The Cheapest Legitimate Route to Dapagliflozin in Iowa

For most Iowa patients, the lowest-cost path depends on insurance status. The sequence below applies the available evidence to a practical decision tree.

Step 1. Check your commercial insurance formulary. If Farxiga appears at Tier 3 or lower with a copay under $60, use that route and apply the AstraZeneca commercial savings card to eliminate the remaining copay. Total monthly cost: potentially $0.

Step 2. If uninsured and income-eligible, apply to AZ&ME Patient Assistance. Processing takes 7 to 14 days but provides brand Farxiga at no cost.

Step 3. If on Iowa Medicaid and not income-eligible for AZ&ME, ask a telehealth provider licensed in Iowa about compounded dapagliflozin from a licensed 503A pharmacy. Compare the compounding pharmacy's price (commonly $80 to $150 per month) against cash-pay brand pricing with GoodRx.

Step 4. If receiving care at an Iowa FQHC or 340B-eligible rural health clinic, ask the pharmacy department whether 340B pricing is available for your prescription.

Step 5. Check the Iowa Prescription Drug Program card at your local pharmacy and present it alongside any other discount; the incremental savings may be $5 to $30 per fill.

No single program covers every Iowa patient, but layering these options often brings the effective monthly cost to under $100 even for patients without commercial insurance.